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Rabies is a viral fatal disease transmitted to humans from bites of infected animals. Due to nearly 95 % of
human infections are related with dog bites, the WHO, OIE and FAO agreed in the implementation of a
worldwide plan for the elimination of dog-mediated human rabies death by 2030. On the other hand, in some
Latin-American countries paralytic bovine rabies transmitted by vampire bats causes economic losses to the
farming industry. In this context, it is important to develop an economic vaccine that could be produced in a
short period of time.
Our research group have been working in the development and validation of a recombinant rabies vaccine
based on virus-like particles (RV-VLPs), expressing the rabies glycoprotein in HEK293 cells1. Performing a
rational design, we carried out the expression vectors construction, stable cell line development and the full
biochemical and morphological characterization of the expressed RV-VLPs. On the other hand, the immune
response triggered by these VLPs in mice was analysed, demonstrating that this new antigen is able to induce a
potent humoral immune response with high titers of neutralizing antibodies. Furthermore, protection against
rabies virus challenge was confirmed in NIH potency test assays, demonstrating that RV-VLPs are an excellent
new generation and virus-free vaccine candidate.
Later, we obtained a stably producer clone able to continuously express RV-VLPs to the culture supernatant
and grow in suspension conditions with serum free medium (SFM)2. The production of the VLPs in 1 and 5 L
bioreactors operated in perfusion conditions was performed, demonstrating that this rabies vaccine candidate
can be produced with high productivity in a conventional recombinant protein production facility, without virus
contention o high biosafety levels needed.
Furthermore, with the goal of obtaining a cost-effective bioprocess able to be transferred to the veterinary
market, we worked in the process optimization in order to reduce the SFM cost; due to this is one of the
principal expenses. Thus, we achieve to adapt our producer clone to a non-expensive in-house culture medium
to be used for perfusion, reducing up to 50 % of the global cost of the culture process3.
In this work, we optimized the vaccine formulation, studying the use of different adjuvants with the aim of
improving the vaccine potency with a minimum antigen concentration required. We obtained a final RV-VLPs
formulation, using a new adjuvant based on cage-like particles with low surface charge density containing
Quil-A® as an immune response stimulator. Rabies VLPs with this formulation are stable for more than 2 years
at 4 °C, obtaining a potency higher than 1 IU/ml when NIH assay was performed after that period of study.
Besides, we carried out safety and serology trials in dogs, cats and livestock, demonstrating that the RV-VLPs
are able to induce a long-lasting immune response in target species, comparable with the commercial vaccines
based on inactivated rabies virus. Besides, following CFR and VICH guidelines we could demonstrate that
RV-VLPs are safe to be used as a rabies vaccine in the studied species.
All these results showed that the obtained RV-VLPs, together with the entire bioprocess developed, are an
excellent vaccine candidate that currently is being transferred to the animal health market.
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